17th Jan 2022 09:32
(Alliance News) - Oxford Biomedica PLC on Monday announced the resignation of Chief Executive Officer John Dawson, though his departure date wasn't set.
The Oxford-based company, which develops gene and cell therapies, said it has already commenced the formal search for a permanent successor.
Dawson has been in his role at Oxford Biomedica for 14 years since 2008, and before that was part of Frazer, Pennsylvania-based biopharmaceutical firm Cephalon Inc, leaving as chief financial officer from 2005 to 2007.
"I am immensely proud of Oxford Biomedica's achievements, and will retire at the appropriate time. Oxford Biomedica is now a global market leader in viral vector technologies for gene and cell therapy," Dawson said.
"I believe this is the right time to start the transition to a new leader given the robustness of the senior team and company as a whole, which is undoubtedly stronger than ever before," he added.
Shares in Oxford Biomedica were down 0.6% at 1,010.00 pence on Monday morning in London.
By Dayo Laniyan; [email protected]
Copyright 2022 Alliance News Limited. All Rights Reserved.
Related Shares:
Oxford Biomedica